HAEMONETICS CORP's ticker is HAE and the CUSIP is 405024100. A total of 244 filers reported holding HAEMONETICS CORP in Q2 2022. The put-call ratio across all filers is 1.27 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,821,193 | -19.1% | 109,636 | -23.1% | 0.59% | -9.9% |
| Q2 2023 | $12,132,620 | +2.9% | 142,502 | 0.0% | 0.66% | -5.6% |
| Q1 2023 | $11,792,041 | +7.4% | 142,502 | +2.1% | 0.70% | +2.5% |
| Q4 2022 | $10,981,270 | -44.3% | 139,622 | -47.6% | 0.68% | -45.5% |
| Q3 2022 | $19,726,000 | +7.4% | 266,463 | -5.5% | 1.25% | +17.1% |
| Q2 2022 | $18,374,000 | +31.1% | 281,893 | +27.1% | 1.06% | +71.8% |
| Q1 2022 | $14,020,000 | +123.6% | 221,768 | +216.8% | 0.62% | +109.5% |
| Q2 2020 | $6,270,000 | -73.3% | 70,013 | -70.3% | 0.30% | -79.9% |
| Q1 2020 | $23,494,000 | -14.5% | 235,740 | -1.5% | 1.47% | +31.2% |
| Q4 2019 | $27,489,000 | +21.8% | 239,240 | +33.7% | 1.12% | +12.4% |
| Q3 2019 | $22,576,000 | +12.6% | 178,977 | +7.4% | 1.00% | +25.5% |
| Q2 2019 | $20,051,000 | +58.2% | 166,617 | +15.0% | 0.80% | +56.7% |
| Q1 2019 | $12,678,000 | +5.2% | 144,927 | +20.3% | 0.51% | -9.8% |
| Q4 2018 | $12,049,000 | – | 120,427 | – | 0.56% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Millrace Asset Group, Inc. | 19,264 | $1,726 | 2.13% |
| Parkman Healthcare Partners LLC | 88,962 | $7,969,216 | 1.46% |
| HEARTLAND ADVISORS INC | 256,414 | $24,435,274 | 1.37% |
| Riverwater Partners LLC | 15,553 | $1,393,238 | 1.27% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 111,100 | $9,952,338 | 1.15% |
| Lisanti Capital Growth, LLC | 78,425 | $7,025,312 | 1.11% |
| Aristotle Capital Boston, LLC | 311,666 | $27,919,054 | 0.90% |
| ROYCE & ASSOCIATES LP | 947,550 | $84,881,529 | 0.86% |
| CHASE INVESTMENT COUNSEL CORP | 18,770 | $1,681 | 0.84% |
| Virtus Investment Advisers, Inc. | 13,662 | $1,223,842 | 0.83% |